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Braulio Muñoz  1 ✉, David L. Haggerty  1 & Brady K Atwood1,2 ✉
The dorsal striatum is a brain region involved in action control, with dorsomedial striatum (DMS) 
mediating goal-directed actions and dorsolateral striatum (DLS) mediating habitual actions. 
Presynaptic long-term synaptic depression (LTD) plasticity at glutamatergic inputs to dorsal striatum 
mediates many dorsal striatum-dependent behaviors and disruption of LTD influences action control. 
Our previous work identified mu opioid receptors (MORs) as mediators of synapse-specific forms of 
synaptic depression at a number of different DLS synapses. We demonstrated that anterior insular 
cortex inputs are the sole inputs that express alcohol-sensitive MOR-mediated LTD (mOP-LTD) in DLS. 
Here, we explore mOP-LTD in DMS using mouse brain slice electrophysiology. We found that contrary 
to DLS, DMS mOP-LTD is induced by activation of MORs at inputs from both anterior cingulate and 
medial prefrontal cortices as well as at basolateral amygdala inputs and striatal cholinergic interneuron 
synapses on to DMS medium spiny neurons, suggesting that MOR synaptic plasticity in DMS is less 
synapse-specific than in DLS. Furthermore, only mOP-LTD at cortical inputs was sensitive to alcohol’s 
deleterious effects. These results suggest that alcohol-induced neuroadaptations are differentially 
expressed in a synapse-specific manner and could be playing a role in alterations of goal-directed and 
habitual behaviors.
Alcohol exposure, both acute and chronic, leads to changes in brain function from the genetic level through to 
changes in cellular function and network alterations1–4. A common outcome of alcohol-induced cellular adap-
tations are changes in synaptic plasticity that likely underlie altered neurocircuit function5,6. One component of 
alcohol use disorder is a transition from flexible goal-directed alcohol use to more habitual or compulsive use 
and this is paralleled by a transition in the activity between the dorsomedial (DMS) and the dorsolateral striatum 
(DLS) subregions of the dorsal striatum7,8. The dorsal striatum is the input nucleus of the basal ganglia and is a key 
region involve in goal-directed learning and habit formation, where the DMS has a primary role in the control of 
outcome-driven behavior and learning and the DLS is important for stimulus-driven behavior and learning7–12. 
As alcohol use shifts from being outcome-driven to becoming more stimulus-driven and compulsive in nature 
during alcohol use disorder development, the balance of action control moves from DMS to DLS7,8,13. The spe-
cialized roles in action control of these two dorsal striatal subregions suggest that the neural circuitry of these two 
areas are differentially affected by ethanol during the development of alcohol use disorders14–16.
GABAergic medium spiny neurons (MSNs) are the striatal output neurons and comprise 95% of dorsal stri-
atal neurons17. MSNs receive glutamatergic inputs from cortex, thalamus, basolateral amygdala, and cholinergic 
interneurons (CINs)18–20. Despite the similarities in neuronal composition and synapse types, the unique inner-
vation of each striatal subregion19 indicates that these different patterns of input may be a critical component 
of determining the function of each region. It is therefore important to determine the “synaptic fingerprints” of 
these inputs: their origins, targeted cell types, protein composition, the types of plasticity they express, and how 
they are impacted by drugs of abuse. For example, it is increasingly understood that dorsal striatal synapses that 
express synaptic plasticity, specifically long-term synaptic depression (LTD) are critical for striatal-dependent 
behaviors and learning, but are also known to be altered by drugs of abuse, including alcohol16,21–24. Elucidating 
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synapse-specific plasticity and the signaling mechanisms that underlie those differences, especially with a focus 
on differences between synapses within dorsal striatal subregions, will allow for a greater understanding of the 
mechanisms of drug-induced changes in behavior.
Our previous work has begun to characterize opioid receptor signaling at specific functional inputs to dorsal 
striatal MSNs5,25. The opioid system is broadly expressed in the dorsal striatum26 and is an important target for 
alcohol use disorder treatment27. In the dorsal striatum, MOR activation presynaptically reduces glutamate and 
GABA release and, through a polysynaptic mechanism, can also reduce dopamine release5,25,28–31. We previously 
found that the activation of MORs on cortical inputs produces a static (non-reversible) form of LTD (mOP-LTD) 
whereas MORs on thalamic inputs generate a labile (transient and reversible) type of plasticity that we operation-
ally define as MOR-mediated short-term depression in both DLS and DMS5,25,32. Furthermore, we also found 
that mOP-LTD occurred at glutamatergic inputs to MSNs from local cholinergic interneurons (CINs) in DLS. 
However, when we used broad electrical stimulation to probe glutamatergic synapses, in vivo exposure to alcohol 
(ethanol) only disrupted mOP-LTD in the DLS and not the DMS5. Using optogenetic targeting mechanisms to 
probe specific synapses for MOR plasticity and sensitivity to ethanol, we found that the only type of cortical input 
that expresses mOP-LTD in DLS is the one originating in the anterior insular cortex (AIC)5, and this mOP-LTD 
was indeed sensitive to ethanol. In the DLS, mOP-LTD at CIN and MOR-mediated short-term depression at thala-
mostriatal synapses were unaffected by ethanol. Given the differential responses of mOP-LTD to ethanol between 
DLS and DMS, we hypothesized that mOP-LTD in the DMS occurs at different glutamatergic synapses than those 
in the DLS. We also predicted that probing of specific inputs might uncover a subpopulation of DMS glutamater-
gic synapses that would be affected by ethanol. In order to test these predictions, we used similar methodologies 
as our previous work, but with a focus primarily on the DMS5. Our primary finding was that mOP-LTD has a 
different profile in DMS than in DLS. It is expressed at multiple DMS inputs rather than one like in DLS. However, 
similar to DLS, inputs from cortex, but not other inputs, were sensitive to the plasticity-ablating effects of ethanol.
Results
AIC and OFC inputs do not express mOP-LTD in the DMS. From our previous work, we broadly 
showed that cortical inputs express mOP-LTD in the DLS and DMS5. We previously probed specific synapses 
in the DLS to identify which synapses expressed mOP-LTD, but did not explore specific synapses in the DMS. 
We demonstrated that AIC inputs are the sole input that expresses mOP-LTD in the DLS5, however AIC has 
lower innervation of the DMS, compared with the DLS19. As a direct follow-up, we first explored mOP-LTD at 
AIC inputs to regions of the striatum more medial to our previous recordings5. To probe these AIC inputs, we 
expressed Channelrhodopsin2 (ChR2) in AIC neurons (Fig. 1A), made brain slices containing DMS and activated 
these AIC inputs using optical stimulation. We activated MORs by bath application of the agonist DAMGO (0.3 
μM) for 5 minutes. AIC inputs did not produce any optically-evoked excitatory postsynaptic current (oEPSCs) 
in the most dorsomedial portion of the area where we typically perform DMS recordings (Fig. 1B–D). However, 
when we changed the recording site to slightly more lateral or ventral portions of the dorsal striatum, we were 
able to evoke oEPSC responses (Fig. 1E). Interestingly, those AIC inputs to those adjacent regions expressed 
mOP-LTD (84 ± 5%; baseline: −96 ± 48 pA vs post-DAMGO: 84 ± 45 pA; Fig. 1F,G). This is consistent with our 
findings in the DLS and also indicates that AIC does not send functional projections to the most dorsomedial 
part of the DMS. Our previous work also demonstrated that mOP-LTD and cannabinoid receptor-mediated LTD 
can functionally interact and that cannabinoid-LTD is expressed at OFC inputs to DMS16,25. Therefore, we pre-
dicted that MOR would also mediate LTD at OFC inputs. To our surprise, we found that OFC projections to the 
DMS did not express mOP-LTD (102 ± 7%; baseline: −190 ± 54 pA vs post-DAMGO: −186 ± 55 pA; Fig. 2B–D). 
These results indicated that, based on our previous work, two of the most likely sources of mOP-LTD in the DMS 
did not in fact express this form of plasticity leading us to explore additional sources.
mOP-LTD is expressed at mPFC and ACC inputs to the DMS. To determine if our previously iden-
tified corticostriatal mOP-LTD in DMS occurs at any other well-validated cortical inputs to the DMS, we tested 
mPFC and ACC inputs (Fig. 3A,B,F,G). Activation of MOR by DAMGO led to a decrease in oEPSC amplitude 
elicited by stimulation of inputs from mPFC (77 ± 8%; baseline: −253 ± 7 pA vs post-DAMGO: −194 ± 22 pA; 
Fig. 3C–E) and ACC regions (83 ± 5%; baseline: −298 ± 21 pA vs post-DAMGO: −247 ± 17 pA; Fig. 3H–J). 
Therefore, MOR activation can inhibit inputs to MSNs within DMS from at least two cortical areas and not just 
one as in the DLS5.
MORs at BLA and CIN inputs induce mOP-LTD in the DMS. We were also interested in whether 
or not other glutamatergic synapses in DMS could express mOP-LTD. Our previous work indicated thalamic 
inputs do not express mOP-LTD in DMS5. BLA is another brain region that sends glutamatergic inputs to the 
DMS and is a known input that expresses alcohol-mediated plasticity19,33. To probe BLA inputs to DMS synapses, 
we expressed ChR2 in the BLA (Fig. 4A) and we found that DAMGO treatment was able to produce mOP-LTD 
at these inputs (77 ± 2%; baseline: −153 ± 24 pA vs post-DAMGO: −119 ± 19 pA; Fig. 4B–D). To explore if 
mOP-LTD is mediated by presynaptic MORs on BLA afferents, we replaced extracellular Ca2+ with Sr2+, and with 
this change we were able to induce asynchronous synaptic release of glutamate after BLA inputs were optically 
evoked in the DMS. As expected, measuring the evoked peak, we detected the presence of mOP-LTD from BLA 
after MOR activation, even in the presence of Sr2+ (59 ± 4%; baseline: −141 ± 38 pA vs post-DAMGO: −84 ± 24 
pA; Fig. 4E–G). We next assessed the properties of the asynchronous events after the evoked peak, measures that 
can be used to ascertain whether drugs effects are presynaptic or postsynaptic34. We found a decrease in the fre-
quency of the events after DAMGO application (baseline: 14 ± 1 Hz vs post-DAMGO: 12 ± 1 Hz; Fig. 4H) without 
changes in amplitude (baseline: 24 ± 2 pA vs post-DAMGO: 22 ± 1 pA; Fig. 4I), rise time (baseline: 0.9 ± 0.04 ms 
vs post-DAMGO: 0.9 ± 0.08 ms; Fig. 4J) or decay time (baseline: 3 ± 0.4 ms vs post-DAMGO: 3 ± 0.5 ms; Fig. 4K). 
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To further characterize the role of presynaptic MORs from BLA, we used a conditional MOR knockout mouse 
(MOR-flox), co-injected with AAV-Cre and AAV-ChR2 vectors to knock out the expression of MORs specifically 
in the BLA and to allow for optogenetic stimulation of the BLA inputs to DMS (Fig. 4L). mOP-LTD appeared to 
be blunted at these BLA inputs (72 ± 11%, Fig. 4M,N) given that DAMGO failed to produce a significant decrease 
in oEPSC amplitude in these mice (baseline: −53 ± 14 pA vs post-DAMGO: −42 ± 14 pA; Fig. 4O). Altogether, 
we suggest that presynaptic MORs in the DMS are responsible for mOP-LTD expressed at BLA inputs.
Given that, we previously found that mOP-LTD occurred at CIN inputs to DLS MSNs5, we also explored 
this possibility in the DMS as well. Using ChATCre mice, we infused a cre-recombinase-dependent AAV-ChR2 
vector to express ChR2 only in CINs in the DMS. We found that the AAV.DIO.ChR2 vector injected in the DMS 
specifically infected CINs (Fig. 5A). Functionally, similar to DLS, we found that activation of CINs produces small 
oEPSCs in MSNs, but these synapses can still express mOP-LTD in the DMS (72 ± 2%; baseline: −107 ± 22 pA vs 
post-DAMGO: −77 ± 15 pA; Fig. 5B–E). Our previous work indicates that it is likely MORs expressed in CINs 
themselves that mediate this mOP-LTD5. Therefore, mOP-LTD is not only expressed at cortical inputs but also at 
BLA and CIN inputs on to MSNs in DMS.
MORs on mPFC, ACC and BLA inputs are indispensable for mOP-LTD. Our data to this point 
indicated that MOR activation was sufficient to induce mOP-LTD at corticostriatal and BLA-DMS inputs. To 
Figure 1. Anterior insular cortex does not send functional projections to the dorsomedial striatum. (A) 
Coronal brain slices from C57BL/6J mice showing the infection of cortical neurons in the AIC following 
infusion of an AAV9.hSyn.ChR2.eYFP vector (Scale bar from left to right = 1 mm, 100 µm and 25 µm). (B) 
Coronal brain slice from C57BL/6J mice showing the projection of AIC infected neurons to the dorsal striatum 
(Scale bar = 1 mm). (C) Schematic representation of 3 different sites of recordings, showing a representative 
trace. (D) 5 minute quantification of responses recorded from sites indicated in C demonstrating no generation 
of EPSCs evoked by optical stimulation (oEPSC). (E–G) Schematic representation of 2 lateral sites and 4 
ventral sites of recordings, showing representative traces of oEPSCs from one lateral and one ventral site before 
(left traces) and after DAMGO treatment (0.3 μM, 5 min). The activation of MOR by DAMGO at these 6 sites 
reduced oEPSC amplitude and induced mOP-LTD. oEPSC amplitudes in MSNs within DMS were significantly 
reduced after DAMGO application (0–10 min baseline v. final 10 min of recording; paired t-test, P = 0.0191, 
t5 = 3.409, n = 6 neurons from 4 mice). Data represent mean ± SEM. *P < 0.05.
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demonstrate that MORs on mPFC, ACC and BLA inputs are indispensable for mOP-LTD, we used MOR-flox 
mice, injected with AAV-Cre vectors to ablate the expression of MORs specifically in the mPFC, ACC and BLA 
(Fig. 6A,B). Here we used electrical stimulation for our recordings in the DMS (Fig. 6A), and found that DAMGO 
application did not produce mOP-LTD in AAV-Cre injected mice (99 ± 6%; Fig. 6C–F), as evidenced by no sig-
nificative changes in eEPSC amplitudes (baseline: −309 ± 24 pA vs post-DAMGO: 313 ± 41 pA; Fig. 6F), but was 
present in AAV-eGFP injected control mice (83 ± 2%; Fig. 6C–F), as evidenced by a significant decrease in eEPSC 
amplitudes (baseline: −294 ± 23 vs post-DAMGO: 248 ± 25 pA; Fig. 6F). Therefore, presynaptic MORs on mPFC, 
ACC and BLA inputs are both indispensable and sufficient to induce mOP-LTD in the DMS.
The effects of in vivo exposure to ethanol on mOP-LTD are specific to corticostriatal synapses. 
We previously reported that mOP-LTD in MSNs within the DMS was not affected by in vivo ethanol exposure5, 
but we just explored those effects using broad electrical stimulation within DMS that would not be selective for 
any specific input5. Therefore, we tested the impact of in vivo ethanol exposure (2.0 g/kg; intraperitoneal, i.p.) 
on the expression of mOP-LTD at mPFC, ACC, and BLA inputs to the DMS. Mice injected with saline (i.p.) 
24 h before harvesting tissue showed normal mOP-LTD at all these DMS synapses (mPFC: 76 ± 8%, Fig. 7A–D; 
ACC: 83 ± 5%, Fig. 7E–H; BLA: 74 ± 4%, Fig. 7I–L) following bath application of DAMGO. Interestingly, in 
mice injected with ethanol 24 h before harvesting tissue, mOP-LTD was ablated at the mPFC and ACC inputs 
(mPFC: 95 ± 2%; ACC: 97 ± 2%; Fig. 7A–H). However, ethanol pre-exposure did not influence mOP-LTD at the 
BLA-DMS inputs (74 ± 3%; Fig. 7I–L). We and others have demonstrated that in vivo ethanol exposure does not 
alter basal synaptic transmission5,35, but to rule out postsynaptic effects of ethanol, we also measured MSN intrin-
sic excitability. Using current clamp recordings, we found no differences between saline and ethanol injected mice 
in the frequency of the action potentials (Supplementary Fig. S1A,B), and in the others membrane parameters 
evaluated (Supplementary Fig. S1C–G). In sum, the data indicate that a single in vivo ethanol exposure is able to 
disrupt the induction of mOP-LTD at corticostriatal synapses, but not at BLA inputs to DMS.
Discussion
Our previous work5 demonstrated the synapse-specificity of mOP-LTD at AIC synapses on to DLS MSNs and 
its singular disruption by ethanol. Using the strictest anatomical definition of what can be classified as “DMS,” 
we did not find evidence of functional AIC inputs to this striatal subregion. This aligns with anatomical analyses 
performed by others19,36. Interestingly we found that mOP-LTD does occur at AIC inputs to regions of dorsal 
striatum that are adjacent to the DMS, closer to ventral striatum (nucleus accumbens) and DLS. In contrast to 
DLS with its lone mOP-LTD-expressing input, our study demonstrated that mOP-LTD occured at multiple inputs 
to DMS. MOR activation on specific corticostriatal (ACC and mPFC) and BLA glutamatergic inputs to the DMS 
all express mOP-LTD. Consistent with our previous work though, only the corticostriatal synapses were sensitive 
Figure 2. MOR activation does not produce LTD of excitatory transmission at orbitofrontal cortex inputs to 
the DMS (A) Coronal brain slice from C57BL/6J mice showing the infection of cortical neurons in the OFC 
following infusion of the AAV9.hSyn.ChR2.eYFP vector and the projection of those infected neurons to the 
dorsal striatum (Scale bar from left to right = 1 mm, 100 µm and 1 mm). (B) Representative optically evoked 
EPSC traces at baseline and after DAMGO (0.3 μM, 5 min) treatment. (C,D) DAMGO does not reduce oEPSC 
amplitude in MSNs of C57BL/6J mice at OFC inputs to DMS (0–10 min baseline v. final 10 min of recording; 
paired t-test, P = 0.6024, t5 = 0.5556; n = 6 neurons from 4 mice).
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to in vivo ethanol exposure. While we cannot completely rule out mOP-LTD at other minor inputs to DMS, 
we conclude that the major source of mOP-LTD in the DMS is at inputs from mPFC, ACC and BLA, since we 
demonstrated that the ablating of MOR expression from those areas is sufficient to disrupt mOP-LTD expression 
in the DMS. The current report together with our previous data demonstrate that MOR-mediated corticostriatal 
LTD is completely presynaptic using a variety of measures, including paired pulse ratio assessments and measures 
of spontaneous EPSCs/miniature EPSCs5,32. In our previous work and here, we have not found data to suggest that 
there are target cell type-specific forms of mOP-LTD plasticity, but we acknowledge that we have not specifically 
tested this possibility here, and this is something that will require further assessment in the future.
Figure 3. mOP-LTD occurs at medial prefrontal and anterior cingulate cortex inputs to the DMS. (A,B) 
Coronal brain slice showing the expression of the infused AAV9.hSyn.ChR2.eYFP in the mPFC and the 
projection of those infected neurons to the dorsal striatum (A: Scale bar from left to right = 1 mm, 500 µm 
and 10 µm; B: Scale bar: 1 mm). (C) Representative oEPSC traces in the DMS of C57BL/6J mice, before and 
after DAMGO application (0.3 μM, 5 min). (D,E) mOP-LTD at mPFC inputs occurs after the application of 
DAMGO. mOP-LTD is defined as the long-lasting reduction in oEPSC amplitudes after DAMGO (0–10 min 
baseline v. final 10 min of recording; paired t-test, P = 0.0313, t5 = 2.965, n = 6 neurons from 4 mice). (F,G) 
Coronal brain slice showing the expression of the infused AAV9.hSyn.ChR2.eYFP in the ACC and the 
projection of those infected neurons to the dorsal striatum (F: Scale bar from left to right = 1 mm, 500 µm and 
10 µm; G: Scale bar: 1 mm). (H) Representative oEPSCs traces before and after DAMGO application. (I,J) mOP-
LTD of ACC inputs occurs after the application of DAMGO (0.3 μM, 5 min). Post-DAMGO application reduced 
the oEPCS amplitudes (0–10 min baseline v. final 10 min of recording; paired t-test, P = 0.0104, t7 = 3.473, n = 8 
neurons from 3 mice). Data represent mean ± SEM. *P < 0.05.
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Figure 4. mOP-LTD occurs at basolateral amygdala inputs to the DMS. (A) Coronal brain slice showing the 
expression of the infused AAV9.hSyn.ChR2.eYFP in the BLA and the somas (Scale bar = 1 mm and 100 µm) 
and the projection of infected neurons to the dorsal striatum of C57BL/6J mice (Scale bar = 1 mm). (B) 
Representative oEPSCs traces at baseline and after DAMGO application (0.3 μM, 5 min). (C,D) DAMGO 
application induced mOP-LTD in the DMS as indicated by a significant reduction in oEPSC amplitude 
(0–10 min baseline v. final 10 min of recording; paired t-test, P = 0.0005, t8 = 5.648, n = 9 neurons from 5 
mice). (E) Representative traces of Sr2+-mediated asynchronous oEPSCs from MSNs before and after DAMGO 
application. (F,G) Activation of MORs (DAMGO 0.3 μM, 5 min) at BLA inputs produces mOP-LTD in the 
DMS, even in the presence of Sr2+ (0–10 min baseline v. final 10 min of recording; paired t-test, P = 0.0202, 
t4 = 3.734, n = 5 from 2 mice). (H–K) Assessment of Sr2+-mediated asynchronous spontaneous EPSCs showed 
a significant reduction in the frequency of the sEPSCs after DAMGO application, but no effect on sEPSC 
amplitude, rise time or decay constant (0–10 min baseline v. final 10 min of recording; paired t-test, P = 0.0418, 
t4 = 2.953, n = 5 from 2 mice). (L) Coronal brain slice showing fluorescent protein expression in the BLA of a 
conditional MOR knockout (MOR-flox) mouse that was co-infused into BLA with AAV9.hSyn.ChR2.eYFP 
and AAV9.hSyn.cre.eGFP vectors (Scale bar = 1 mm and 500 µm). (M) Representative oEPSC traces at baseline 
and after DAMGO application. (N,O) In mice with MORs knocked out from BLA, DAMGO did not produce 
a significant change in oESPC amplitudes in DMS (0–10 min baseline v. final 10 min of recording; paired t-test, 
P = 0.2195, t5 = 1.403, n = 6 neurons from 2 mice). Data represent mean ± SEM. *P < 0.05, ***P < 0.001.
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We previously demonstrated that cannabinoid receptor-mediated LTD occurs at OFC inputs to DMS16, but 
in the present study we found that OFC-DMS synapses did not respond to MOR agonist treatment. These data, 
in combination with our findings from DLS5, suggest that OFC inputs lack expression of presynaptic MORs. This 
was surprising to us as we had previously found that mOP-LTD and cannabinoid-LTD are mutually occlusive 
with one another25 and thought it likely that since OFC inputs to dorsal striatum express cannabinoid-LTD, 
that we would also find mOP-LTD at these synapses16. Future work will need to resolve how mOP-LTD and 
cannabinoid-LTD interact, if they are indeed expressed at the same synapses or if they display a heterosynaptic 
relationship.
In addition to identifying mOP-LTD at specific DMS inputs, we also identified the presence of mOP-LTD at 
CIN inputs on to MSNs within the DMS, consistent with our previous work5. CINs are an important component 
of the network balance of the striatum37, and can affect corticostriatal cannabinoid-LTD38, thalamic glutamate 
release39, and dopamine tone40. In addition to our work, others have reported on the role of MOR in modulating 
CIN activity30,41. Future work will need to explore the specific role of CIN-driven glutamate release and the role 
of MOR signaling in these neurons.
While many others have reported the effects of MORs on glutamatergic synaptic transmission in dorsal stri-
atum5,25,28,29,31, until recently, only one other study has specifically explored regulation of DMS transmission via 
presynaptic MORs28. These investigators found that the only source of MOR-mediated depression of glutamater-
gic transmission in the DMS occurs at thalamic inputs28. Our findings contradict this study, but there are a few 
possible explanations for the different findings. One possible explanation is the duration of DAMGO exposure. 
The other study did not report the duration of agonist exposure and representative current traces implied that 
DAMGO might be having some effect that was also not reversed by the MOR antagonist CTAP. However no time 
course was provided so it was not possible to evaluate whether MORs were sufficiently engaged to induce LTD. 
Another likely explanation is methodological. Our recording conditions only block GABAA receptor-mediated 
transmission, whereas this other study used a cocktail of metabotropic GABA, glutamate, and acetylcholine 
receptor antagonists in addition to antagonists of GABA and nicotinic acetylcholine ionotropic receptor antag-
onists. Our study here does not rule out the necessity of other neurotransmitters being co-factors for mOP-LTD 
and indeed our earlier work suggested that mGluR5 transmission might be an important element of opioid-LTD 
in DLS, at least for the form mediated by endogenous opioids25. Much more work is required to decipher the 
mechanisms of mOP-LTD including if induction of opioid-LTD by endogenous opioids in DMS utilizes similar 
mechanisms as in DLS25.
We previously reported that mOP-LTD in the DMS was not affected by ethanol exposure5. The critical differ-
ence here is that the previous study did not explore synapse-specific MOR plasticity like we performed here, but 
rather broadly probed glutamate transmission. Using local electrical stimulation, it is difficult to ascertain the 
Figure 5. Cholinergic interneuron synapses on to DMS MSNs express mOP-LTD. (A) Coronal brain slice 
showing the infection of cholinergic interneurons (CINs) with the infused AAV.DIO.ChR2.eYFP (green) and 
the colocalization with anti-ChAT antibody (red) in the dorsal striatum of ChATCre mice (Scale bar = 250 µm 
and 50 µm). (B) Coronal brain slice showing the infection of cholinergic interneurons with the infused AAV.
DIO.ChR2.eYFP vector in the dorsal striatum of ChATCre mice (Scale bar = 1 mm). (C) Representative traces 
of oEPSCs recorded in MSNS following optogenetic stimulation of CINs before and after DAMGO application. 
(D-E) Activation of MORs (DAMGO 0.3 μM, 5 min) at CIN inputs in ChATCre mice produces mOP-LTD in 
the DMS. DAMGO application reduced the oEPSC amplitudes (0–10 min baseline v. final 10 min of recording; 
paired t-test, P = 0.003, t7 = 4.429, n = 8 from 4 mice). Data represent mean ± SEM. **P < 0.01.
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relative contribution of various cortical, thalamic, amygdalar, and cholinergic interneuron inputs to any given 
MSN. Our previous data and the data presented here show that ethanol has synapse-type-specific effects: ethanol 
disrupted mOP-LTD at corticostriatal, but not other synapse types. Altogether, these results could explain the 
lack of ethanol effects on mOP-LTD in the DMS in our previous work, possibly because the ethanol-insensitive 
MOR-mediated plasticity at non-cortical inputs to DMS MSNs blunted the observation of ethanol’s effects on 
mOP-LTD at corticostriatal synapses, although additional work will need to be performed to validate this hypoth-
esis. Taking these data together with our previous work indicates that there is some mechanism that makes MOR 
plasticity at corticostriatal synapses sensitive to disruption by ethanol, but MOR plasticity at thalamic, amygda-
lar, and CIN glutamatergic inputs insensitive. Future work will determine if ethanol needs a particular synaptic 
environment to affect mOP-LTD and if this is due to different mechanisms of MOR plasticity at these different 
synapses or if it is due to upstream effects of ethanol on cortex. Others have demonstrated that ethanol is able 
to alter LTD mediated by other presynaptic Gi/o-coupled GPCRs such as cannabinoid-LTD in DLS15,24,42 and 
mGluR2-LTD in DLS and DMS of adolescent mice43. Ethanol is also known to disrupt other forms of LTD at mul-
tiple other synapse types in the brain6. It will be of great interest if ethanol has a common mechanism of action at 
all of these different synapses.
Our data provide some interesting possibilities for how ethanol may influence DMS-mediated goal-directed 
behavior given that its effects, in relation to mOP-LTD, are limited to cortical afferents. A loss of LTD at 
Figure 6. MORs on mPFC, ACC and BLA inputs are indispensable for the induction of mOP-LTD in the DMS. 
(A) Schematic figure of the triple injection paradigm enabling knock out of MOR expression in mPFC, ACC 
and BLA in MOR-flox mice. An AAV vector encoding for either cre-recombinase (AAV.hSyn.cre) or eGFP 
(AAV.hSyn.eGFP) was injected 8 weeks prior to recordings. (B) Coronal brain slice showing the infection of 
cortical and BLA neurons (Scale bar = 1 mm). (C) Representative electrically-evoked synaptic traces from 
AAV-eGFP-infused (open black circle) and AAV-Cre-infused (open grey square) mice, obtained in the DMS 
before and after DAMGO (0.3 μM, 5 min) showing the loss of mOP-LTD mediated by mPFC, ACC and BLA 
MORs. (D,E) After DAMGO application, eGFP-infected brain slices show mOP-LTD, but not brain slices from 
mice that were infused with AAV-Cre (last 10 minutes, Welch’s t-test, P = 0.0326). (F) eEPSC amplitudes were 
reduced after DAMGO application only in AAV-eGFP-infused mice, and not in AAV-Cre-infected MOR-flox 
mice, indicating that MORs from mPFC, ACC, and BLA are indispensable for MOR-mediated glutamatergic 
depression in the DMS (0–10 min baseline v. final 10 min of recording; paired t-test, eGFP: P < 0.0001, 
t7 = 11.24, n = 8 from 3 mice; cre: P = 0.8712, t8 = 0.1674, n = 9 from 3 mice). Data represent mean ± SEM. 
*P < 0.05, ***P < 0.001.
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specific cortical inputs could permit larger synaptic drive from these cortical regions resulting in greater control 
over striatal activity. For example, one study showed that LTD induction at mPFC synapses within the DMS 
decreased alcohol-seeking behavior, while LTP induction increased this behavior22. A loss of mOP-LTD at these 
same synapses may be akin to the LTP conditions and may therefore play a role in increased alcohol-seeking 
behavior in ethanol-dependent animals. Even though mOP-LTD at BLA inputs was insensitive to ethanol 
exposure, BLA inputs may have a role in ethanol and drug relapse and therefore MORs may modulate these 
amygdalostriatal-mediated behaviors44,45. In the future, it will also be important to not only investigate the origins 
of MOR-sensitive synapses, but also the afferent targets: D1- or D2-expressing MSNs (direct or indirect pathway 
respectively) given their different roles in DMS-mediated ethanol-related behaviors46.
In conclusion, in combination with our previous work, we have demonstrated that MORs appear to only 
regulate specific dorsal striatum synapses with each of these different regions expressing specific forms of 
MOR-mediated plasticity (LTD or short-term depression). In addition, some mOP-LTD-expressing synapses are 
sensitive to ethanol and others insensitive. Altogether these findings indicate that specific striatal glutamatergic 
Figure 7. A single in vivo ethanol exposure prevents induction of mOP-LTD at mPFC and ACC inputs, but 
not at BLA synapses. C57BL/6J mice that were previously infused with AAV.hSyn.ChR2 in mPFC, ACC or BLA 
were injected (intraperitoneal) with saline or ethanol (EtOH, 2 g/kg). 24 h after this injection, oEPSCs in MSNs 
from the DMS were recorded. (A) Representative oEPSC traces from mPFC input stimulation in the DMS 
before and after DAMGO (0.3 μM, 5 min) application in saline- (blue traces) and ethanol- (red traces) injected 
mice. (B,C) Ethanol blunted mOP-LTD induced by DAMGO (0.3 μM, 5 min) from mPFC synapses in the 
DMS (last 10 minutes, Welch’s t-test, P = 0.0355). (D) Reduction of oEPSC amplitudes occurred only in saline-
injected mice (baseline v. final 10 min of recording; paired t-test, P = 0.007, t7 = 3.768, n = 8 from 3 mice), but 
not in ethanol-injected ones (P = 0.068, t8 = 2.1, n = 9 from 3 mice). (E) Representative oEPSC traces following 
ACC input stimulation in the DMS before and after DAMGO application in saline- (blue traces) and ethanol- 
(red traces) injected mice. (F,G) Ethanol disrupted mOP-LTD induced by DAMGO (0.3 μM, 5 min) from ACC 
synapses in the DMS (Welch’s t-test, P = 0.0304). (H) Saline-injected mice expressed normal mOP-LTD in the 
DMS with a reduction in oEPSC amplitudes after DAMGO (0–10 min baseline v. final 10 min of recording; 
paired t-test, P = 0.0124, t8 = 3.211, n = 9 from 3 mice), but ethanol-injected mice showed disrupted mOP-LTD, 
with no difference in oEPSC amplitudes (P = 0.0939, t7 = 1.938, n = 8 from 3 mice). (I) Representative oEPSC 
traces following BLA input stimulation in the DMS before and after DAMGO (0.3 μM, 5 min) application in 
saline- (blue traces) and ethanol- (red traces) injected mice. (J,K) Ethanol does not affect mOP-LTD induced 
by DAMGO at BLA inputs (0.3 μM, 5 min) in the DMS (final 10 minutes, unpaired Student’s t-test, P = 0.9993, 
t16 = 0.0009). (L) Both treatments, saline (0–10 min baseline v. final 10 min of recording; paired t-test, 
P = 0.0036, t8 = 4.057, n = 9 from 3 mice) and ethanol (P = 0.0056, t8 = 3.759, n = 9 from 3 mice), do not affect 
mOP-LTD at BLA inputs. Data represent mean ± SEM. *P < 0.05, **P < 0.01.
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synapses express unique complements of signaling processes that result in different types of plasticity being 
expressed that are differentially sensitive to drugs of abuse. The specific molecular machinery that creates these 
differences may be a “synaptic fingerprint” of drug-sensitive synapses. In the future, it will be important to further 
elucidate the synaptic fingerprints of not only MOR signaling at specific striatal synapses, but also other forms of 
plasticity, to mechanistically understand ethanol’s network effects in order to identify novel treatments for alcohol 
use disorder and drug addiction.
Methods
All experiments were performed similar to our previous studies with some experiment-specific modifica-
tions5,25,47,48. These methods are described in brief below.
Animals and materials. Animal care and experimental protocols for this study were approved by the 
Institutional Animal Care and Use Committee at the Indiana University School of Medicine and all guidelines 
for ethical protocols and care of experimental animals established by the NIH (National Institutes of Health, 
Maryland, USA) were followed. Male C57BL/6J mice were ordered from the Jackson Laboratory (Bar Harbor, 
Maine, USA). ChATCre transgenic mice were bred and genotyped in-house (Original stock strain: ChATCre: 
JAX #006410). Conditional MOR knockout mice (MOR-flox) were a generous gift from Dr. Jennifer Whistler (UC 
Davis) and have been previously described5,49. All transgenic mice used in these studies have been backcrossed 
to C57BL/6J mice for a minimum of 7 generations. The mice used in these studies were between PND 60–100 
at the time of experimentation (with the exception of ChATCre mice that were ~PND 60–120 and MOR-flox 
AAV-cre-injected mice ~PND 105–126). Animals were group-housed in a standard 12-h light/dark cycle (lights 
on at 0800) at 50% humidity. Food and water were available ad libitum.
Brain slice preparation. Mice were euthanized via decapitation under deep isoflurane anesthesia, and the 
brain was quickly excised and placed in an ice-cold cutting solution containing (in mM): 194 sucrose, 30 NaCl, 
4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, 10 Glucose saturated with a mixture of 95% O2 and 5% CO2, and 
sliced to a thickness of 280 μm on a vibratome (Leica VT1200S, Germany). Slices were transferred to an artificial 
cerebrospinal fluid (aCSF) solution containing (in mM): 124 NaCl, 4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, 
10 Glucose, 2 CaCl2 (310–320 mOsm) saturated with 95% O2/5% CO2 at 30 °C for 1 hr before being moved to 
room temperature. When ready for recording, slices were transferred to a recording chamber continuously per-
fused with aCSF solution saturated with 95% O2/5% CO2.
Electrophysiology recordings. Whole-cell recordings of excitatory postsynaptic currents (EPSCs) in 
MSNs were carried out at 29–32 °C and aCSF was continuously perfused at a rate of 1–2 ml/min. Recordings were 
performed in the voltage clamp configuration using a Multiclamp 700B amplifier and a Digidata 1550B (Axon 
Instruments, Union City, CA). Slices were visualized on an Olympus BX51WI microscope (Olympus Corporation 
of America). MSNs were identified by their size, membrane resistance, and capacitance. Picrotoxin (50 μM) 
was added to the aCSF for recordings to isolate excitatory transmission. Patch pipettes were prepared from 
filament-containing borosilicate micropipettes (World Precision Instruments) using a P-1000 micropipette puller 
(Sutter Instruments, Novato, CA), having a 2.0–3.5 MΩ resistance. The internal solution contained (in mM): 
120 CsMeSO3, 5 NaCl, 10 TEA-Cl, 10 HEPES, 5 lidocaine bromide, 1.1 EGTA, 0.3 Na-GTP and 4 Mg-ATP (pH 
7.2 and 290–310 mOsm). MSNs were voltage clamped at −60 mV for the duration of the recordings. To detect 
asynchronous glutamatergic transmission, aCSF Ca2+ was replaced with Sr2+ (2 mM). For electrically evoked 
recordings, a twisted tungsten bipolar stimulating electrode (PlasticsONE, Roanoke, VA) was placed at the bor-
der of the overlying corpus callosum. eEPSCs were generated by a DS3 Isolated Current Stimulator (Digitimer, 
Ft. Lauderdale, FL) every 20 s and stimulus intensity was adjusted to produce stable electrically-evoked EPSCs 
(eEPSCs) of 200–600 pA in amplitude prior to the initiation of experimental recording. Data were acquired using 
Clampex 10.3 (Molecular Devices, Sunnyvale, CA). Series resistance was monitored and only cells with a stable 
series resistance (less than 25 MΩ and that did not change more than 15% during recording) were included for 
data analysis. Recordings were made 2–7 h after euthanasia.
Viral injections. Male ChATCre mice were anesthetized with isoflurane and stereotaxically injected with 
the adeno-associated viral (AAV) vector, AAV9.EF1a.DIO.ChR2(H134R)-eYFP (Penn Vector Core/Addgene) 
to drive expression of the photosensitive cation channel, channelrhodopsin2 (ChR2), solely in CINs. Bilateral 
injections were made into dorsal striatum at coordinates A/P: +0.7, M/L: ±1.5, D/V: −3.1 (100 nl/injection, 25 nl/
min infusion rate). Mice were allowed to recover for at least 2 weeks before brain slices were made for electro-
physiological recordings. Male C57BL/6J mice were anesthetized with isoflurane and stereotaxically injected with 
the adeno-associated viral (AAV) vector, AAV9.hSyn.ChR2(H134R)-eYFP (Penn Vector Core/Addgene) to drive 
ChR2 expression in mPFC, OFC, ACC, BLA and AIC neurons. Bilateral injections were made into mPFC at coor-
dinates A/P: +1.9, M/L: ±0.3, D/V: −2.3 (100 nl/injection, 25 nl/min infusion rate); OFC: A/P: +2.7, M/L: ±1.75, 
D/V: −2.25 (100 nl/injection, 25 nl/min infusion rate); ACC: A/P: +1.4, M/L: ±0.3, D/V: −1.75 (100 nl/injection, 
25 nl/min infusion rate); BLA: A/P: −1.6, M/L: ±3.35, D/V: −4.5 (100 nl/injection, 12.5 nl/min infusion rate) and 
AIC: A/P: +2.4, M/L: ±2.3, D/V: −2.25 (50 nl/injection, 12.5 nl/min infusion rate).
To induce specific oEPSCs from BLA projection neuron MOR knockout mice, MOR-flox mice were anesthe-
tized with isoflurane and stereotaxically injected with the combination of AAV9.hSyn.Cre.eGFP plus AAV9.hSyn.
ChR2.eYFP (Penn Vector Core/Addgene). Bilateral injections were made into BLA at coordinates: A/P: −1.6, 
M/L: ±3.35, D/V: −4.5 (100 nl/injection, 12.5 nl/min infusion rate). MOR-flox mice were allowed to recover for 
at least 8 weeks to allow for adequate ablation of MOR expression before brain slices were made for electrophys-
iological recordings.
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To produce triple mPFC, ACC and BLA projection neuron MOR knockout mice, MOR-flox mice were anes-
thetized with isoflurane and stereotaxically injected with AAV9.hSyn.Cre.eGFP or AAV9.hSyn.eGFP as control 
(Penn Vector Core/Addgene). Bilateral injections were made into mPFC, ACC and BLA at coordinates: mPFC: 
A/P: +1.9, M/L: ±0.3, D/V: −2.3 (100 nl/injection, 25 nl/min infusion rate); ACC: A/P: +1.4, M/L: ±0.3, D/V: 
−1.75 (100 nl/injection, 25 nl/min infusion rate) and BLA: A/P: −1.6, M/L: ±3.35, D/V: −4.5 (100 nl/injection, 
12.5 nl/min infusion rate). MOR-flox mice were allowed to recover for at least 8 weeks to allow for adequate abla-
tion of MOR expression before brain slices were made for electrophysiological recordings.
Immunohistochemistry. ChATCre mice previously infused with AAV9.EF1a.DIO.ChR2(H134R)-eYFP vec-
tor (Penn Vector Core/Addgene) were overdosed with a ketamine/xylazine (87.5 mg/kg ketamine and 12.5 mg/kg 
xylazine) cocktail (0.1 ml/20 g mouse weight) and then perfused transcardially with cold (4 °C) phosphate-buffered 
saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS. Brains were extracted and placed in cold 4% PFA in 
PBS for 24 hours and then in cold 30% sucrose in double-distilled water for an additional 24 hours. Using a vibra-
tome, 50 µm coronal sections were collected in serial order in cold PBS. Free-floating slices were incubated in 5% nor-
mal goat serum (NGS) in phosphate-buffered saline + Triton X-100 (PBST) on an orbital shaker for 1 hour at room 
temperature (RT). Immunostaining for the Choline Acetyltransferase (ChAT) protein was accomplished by using a 
primary antibody directed against ChaT (Anti-Choline Acetyltransferase, Sigma, cat.no. AB144P, diluted 1:100) in 
5% NGS in PBST overnight on an orbital shaker at 4 °C. Sections were washed in PBST (3 times for 10 minutes) and 
then incubated in a secondary antibody (Donkey anti-Goat IgG (H + L), Alexa Fluor 568, Life Technologies, cat. no. 
A-11057, diluted 1:200) in 5% NGS in PBST for 2 hours on an orbital shaker at RT. Sections were washed in PBST 
(3 times for 10 minutes) and then mounted onto slides. Slides were cover slipped using Vectashield Hard Mount Set 
Medium + DAPI (Vector Laboratories), dried overnight, and then sealed with clear nail polish. Immunofluorescent 
images were acquired using a microscope (Keyence BX-800) with a 20x and 60x objective.
Optogenetic recordings. AAV-DIO-ChR2-injection in ChATCre mice allows for targeted recombination 
manipulations only within CINs5,50,51. They were used in the present study to express ChR2 in dorsal striatal 
CINs. AAV-ChR2 injection in C57BL/6J mice was performed to target ChR2 expression to inputs from mPFC, 
OFC, ACC, BLA and AIC to DMS. AAV-ChR2 injection in MOR-flox mice was performed to target ChR2 
expression to inputs from BLA to DMS. Optically-evoked EPSCs (oEPSCs) in MSNs were produced in brain 
slices using 470-nm blue light (5-ms exposure time) delivered via field illumination through the microscope 
objective. Light intensity was adjusted to produce stable oEPSCs of 200–600-pA amplitude prior to experimental 
recording. oEPSCs were evoked every 30 s. Prior to recording, brain slices were imaged via an Olympus MVX10 
microscope (Olympus Corporation of America) to verify eYFP-tagged ChR2 expression in injected ChATCre+, 
MOR-flox and C57BL/6J mice or properly localized cre-recombinase expression (indicated by eYFP fluores-
cence). Brightfield images were used to draw boundaries of anatomical landmarks in low-magnification images. 
High-magnification representative images were acquired using a microscope (Keyence BX-800) with 4x and 20x 
objectives. Drawn outlines of anatomical boundaries in high-magnification representative images were deter-
mined by comparing the images’ maximum intensities to a mouse brain atlas (Franklin and Paxinos, The Mouse 
Brain, Elsevier, 2007). Representative images of brain slices in figures also indicate A/P coordinates from Bregma.
Ethanol exposure. Mice (PND 80–100) received intraperitoneal (i.p.) injections of 0.9% NaCl saline (10 ml/
kg) or 2 g/kg ethanol. Brain slices were obtained for electrophysiological recordings (as described above) 24 hr after 
ethanol injection. Animals were randomized to treatments, but the experimenter was not blinded to treatments.
Reagents. We used the MOR agonist [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin (DAMGO; H-2535, Bachem), 
ethanol (ethanol, E7148, Sigma-Aldrich) and GABAA receptor antagonist picrotoxin (PTX, P1675, Sigma-Aldrich). 
Other reagents used for making solutions were purchased from Sigma-Aldrich or Fisher Scientific.
Sample size. The target number of samples in each group for behavioral, biological, and electrophysiological 
experiments was determined based on numbers reported in published studies5,25.
Replication. All sample sizes indicated in figures for electrophysiological experiments represent biological 
replicates. N equals the number of slices recorded. 1 neuron was recorded from per brain slice.
Data analyses. Unless otherwise indicated, data are presented as the mean ± SEM. The analyses of nor-
mally distributed data were performed using two-tailed unpaired or two-tailed paired Student’s t tests following 
an F test to confirm similar variances. Non-normally distributed data were analyzed using two-tailed Welch’s 
t test for unpaired data (Figs. 6E, 7C,G). Data that were analyzed using this test are indicated in the figure leg-
ends. Statistical analyses were performed with Prism 7 (GraphPad, La Jolla, CA). The level of significance was 
set at P < 0.05 for all analyses. Representative traces are the average baseline EPSC (1–10 min) and average 
post-treatment EPSC of final 10 min of recording. Exclusion of individual data points was determined using a 
ROUT outlier calculator (Q = 1%) included in the Prism 7 software package.
Data availability
All data are available from the authors upon reasonable request.
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